Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer

Int J Pharm. 2023 Apr 5:636:122844. doi: 10.1016/j.ijpharm.2023.122844. Epub 2023 Mar 14.

Abstract

Pancreatic cancer is a malignant disease with high mortality, and its systemic treatment strategy mainly focuses on chemotherapy. Yet, the overall prognosis of pancreatic cancer patients is still extremely poor with a low survival rate. Gemcitabine (GEM) is a widely used chemotherapeutic agent for the treatment of pancreatic cancer. However, GEM chemoresistance remains the major challenge. In this study, we prepared calcium carbonate nanoparticles (CaCO3 NPs) loaded with a nucleotide reductase inhibitor (Triapine) and GEM to suppress the GEM resistance of pancreatic cancer cells (PANC-1/GEM) and solve the problem of poor solubility of Triapine. CaCO3-GEM-Triapine NPs nano-formulations enhanced the therapeutic effect of GEM-based chemotherapy by inhibiting cancer cell proliferation, migration, and resistance to GEM using both 2D PANC-1/GEM cells and 3D tumor spheroids. The study indicated that CaCO3 NPs loaded with GEM and Triapine could provide an effective treatment option to overcome drug resistance in pancreatic cancer.

Keywords: Calcium carbonate nanoparticles; Drug resistance; Gemcitabine; Pancreatic cancer; Triapine.

MeSH terms

  • Cell Line, Tumor
  • Deoxycytidine / pharmacology
  • Gemcitabine
  • Humans
  • Nanoparticles*
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / pathology

Substances

  • Gemcitabine
  • 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
  • Deoxycytidine